keyword
MENU ▼
Read by QxMD icon Read
search

ranexa

keyword
https://www.readbyqxmd.com/read/23329466/ranolazine-a-review-of-its-use-as-add-on-therapy-in-patients-with-chronic-stable-angina-pectoris
#1
REVIEW
Gillian M Keating
Extended-release ranolazine (ranolazine ER) [Ranexa(®)] is an antianginal agent that achieves its effects via a novel mechanism of action (inhibition of the late phase of the inward sodium current), without affecting heart rate or blood pressure (BP). This article reviews the efficacy, safety and tolerability of ranolazine ER as add-on therapy in patients with chronic stable angina pectoris, as well as summarizing its pharmacological properties and its use in non-ST-elevation acute coronary syndromes. In the CARISA and ERICA trials, add-on therapy with ranolazine ER improved exercise tolerance and/or reduced angina frequency and nitroglycerin use in patients with chronic stable angina; benefits were seen across a variety of patient subgroups...
January 2013: Drugs
https://www.readbyqxmd.com/read/23116083/persistent-current-blockers-of-voltage-gated-sodium-channels-a-clinical-opportunity-for-controlling-metastatic-disease
#2
REVIEW
Mustafa B A Djamgoz, Rustem Onkal
A range of experimental and clinical data suggests strongly (i) that metastatic progression in carcinomas is accompanied (maybe even preceded) by upregulation of functional voltage-gated sodium channels (VGSCs) and (ii) that VGSC activity enhances cancer cell invasiveness. First, this review outlines the available in vitro and in vivo evidence for the VGSC expression and its proposed pathophysiological role. Second, we question the mechanism(s) whereby VGSC activity can induce such a cancer-promoting effect...
January 1, 2013: Recent Patents on Anti-cancer Drug Discovery
https://www.readbyqxmd.com/read/21105855/perspective-does-ranolazine-have-potential-for-the-treatment-of-atrial-fibrillation
#3
REVIEW
Jules C Hancox, Sheila A Doggrell
Atrial fibrillation is the most common arrhythmia seen in clinical practice, and novel pharmacological approaches for treatment are sought. Ranolazine (Ranexa; N-(2,6-dimethylphenyl)-2-[4-(2-hydroxy-3-[2-methoxyphenoxy]propyl)piperazin-1-yl]acetamide) is used clinically for the treatment of angina pectoris. Evidence is reviewed from both pre-clinical and clinical studies, which suggests that ranolazine also exhibits antiarrhythmic activity with growing evidence for atrio-selectivity. Further work is required in order to explore more fully the potential of ranolazine in the treatment of atrial fibrillation...
December 2010: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/20812421/ask-the-doctor-a-year-ago-i-had-an-orchiectomy-for-prostate-cancer-my-psa-is-now-0-74-not-long-afterward-i-had-two-cardiac-stents-implanted-i-still-have-some-angina-and-shortness-of-breath-i-started-ranexa-a-couple-of-weeks-ago-which-helps-my-angina-do-you
#4
https://www.readbyqxmd.com/read/20449698/ranolazine-ranexa-in-the-treatment-of-chronic-stable-angina
#5
REVIEW
Sajid Aslam, David Gray
Ischemic heart disease is the major cause of morbidity and mortality in the Western world. Patients often suffer a reduction in quality of life due to chronic stable angina, but therapeutic options can be limited due to concerns for heart rate and blood pressure, as well as side effect profiles. Even revascularization therapy has its limitations and newer agents are required to help in this battle for symptomatic relief. Ranolazine (Ranexa(R), A. Menarini Pharma UK, High Wycombe, UK) is a drug with a novel mechanism of action that has been shown in several large trials to be an efficacious adjunctive agent in reducing symptoms of chronic stable angina...
April 2010: Advances in Therapy
https://www.readbyqxmd.com/read/19737166/chronic-angina-and-the-treatment-with-ranolazine-facts-and-recommendations
#6
REVIEW
Heather Carrier Milne, April Hazard Vallerand
More than 6 million people in the United States are affected by chronic angina. On January 27, 2006, the US Food and Drug Administration (FDA) approved a new medication for the treatment of chronic stable angina called ranolazine (Ranexa). This is the first angina drug approved by the FDA in over a decade. The unique thing about this drug is that it falls into a new class of therapies in that it works at the level of cellular metabolism in decreasing demand on the cardiac tissue. There are many factors to consider when prescribing this medication including past studies, dosing, and education...
September 2009: Progress in Cardiovascular Nursing
https://www.readbyqxmd.com/read/19333133/a-novel-mechanism-for-the-treatment-of-angina-arrhythmias-and-diastolic-dysfunction-inhibition-of-late-i-na-using-ranolazine
#7
REVIEW
Lars S Maier
Inhibition of the persistent or late Na current (INa) using ranolazine (Ranexa) represents a novel mechanism of action that was approved in the United States in 2006 and only recently in the European Union for use in patients with stable angina pectoris. In general, myocardial ischemia is associated with reduced adenosine triphosphate fluxes and decreased energy supply, resulting in severe disturbances of intracellular ion homeostasis in cardiac myocytes. In the recent years, increased late INa was suggested to contribute to this phenomenon by elevating intracellular Na concentration with subsequent rise in diastolic Ca levels by means of the sarcolemmal Na-Ca exchange system...
October 2009: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/19016575/ranolazine-a-review-of-its-use-in-chronic-stable-angina-pectoris
#8
REVIEW
Gillian M Keating
Extended-release ranolazine (ranolazine ER) [Ranexa] is a piperazine derivative with a novel mechanism of action that was recently approved in the EU for use as add-on therapy in patients with stable angina pectoris. Ranolazine ER achieves its antianginal effect without affecting heart rate or blood pressure (BP) to a clinically significant extent. Results of well designed, placebo-controlled, short-term studies demonstrate that add-on therapy with ranolazine ER in patients with chronic stable angina improves exercise performance, and reduces anginal frequency and nitroglycerin use...
2008: Drugs
https://www.readbyqxmd.com/read/18322148/antitorsadogenic-effects-of-n-2-6-dimethyl-phenyl-4-2-hydroxy-3-2-methoxyphenoxy-propyl-1-piperazine-ranolazine-in-anesthetized-rabbits
#9
Wei-Qun Wang, Chelsea Robertson, Arvinder K Dhalla, Luiz Belardinelli
Ranolazine [Ranexa; (+/-)-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine] is novel anti-ischemic agent that has been shown to inhibit late I(Na) and I(Kr) and to have antiarrhythmic effects in various preclinical in vitro models. This study was undertaken to investigate the effects of ranolazine on drug-induced Torsade de Pointes (TdP) in vivo. TdP was induced by an I(Kr) blocker, clofilium, in anesthetized, alpha(1)-agonist-sensitized rabbits. Clofilium prolonged QT interval corrected for heart rate (QTc) (52 +/- 9%) and monophasic action potential duration (MAPD)(90) (56 +/- 9%) and caused TdP in eight of eight rabbits...
June 2008: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/18221101/ranolazine-a-partial-fatty-acid-oxidation-inhibitor-its-potential-benefit-in-angina-and-other-cardiovascular-disorders
#10
REVIEW
Bharti Bhandari, L Subramanian
Chronic Angina resistant to medical treatment with hemodynamically acting agents is a major problem in clinical setup. For such patients, large number of clinical trials have documented the beneficial effect of Ranolazine. It acts as an anti-anginal agent that controls myocardial ischemia through intracellular metabolic changes. Ranolazine is a partial fatty acid oxidation inhibitor which shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation. Since the oxidation of glucose requires less oxygen than the oxidation of fatty acids, ranolazine can help maintain myocardial function in times of ischemia...
January 2007: Recent Patents on Cardiovascular Drug Discovery
https://www.readbyqxmd.com/read/17595750/ranolazine-ranexa-for-chronic-stable-angina
#11
S Ndegwa
(1) Ranolazine-- an adjunctive treatment to beta-blockers, calcium channel blockers, or long-acting nitrates-- is indicated for patients with chronic stable angina who have not responded to standard anti-anginal therapy. (2) In three randomized controlled trials (RCTs), ranolazine, in combination with standard anti-anginal medications, led to modest but statistically significant improvements in exercise duration, and reductions in the frequency of angina episodes and nitroglycerin consumption, when compared to standard anti-anginal medications only...
June 2007: Issues in Emerging Health Technologies
https://www.readbyqxmd.com/read/17083271/spotlight-on-ranolazine-in-chronic-stable-angina-pectoris
#12
REVIEW
M Asif A Siddiqui, Susan J Keam
Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. While the exact mechanism of action of ranolazine is not known, its antianginal and anti-ischemic effects do not appear to depend upon changes in BP or heart rate. An extended-release (ER) oral formulation of ranolazine has been developed to facilitate twice-daily administration whilst maintaining therapeutically effective plasma concentrations...
2006: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/16770296/ranolazine-ranexa-for-chronic-angina
#13
(no author information available yet)
No abstract text is available yet for this article.
June 5, 2006: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/16620147/ranolazine-a-review-of-its-use-in-chronic-stable-angina-pectoris
#14
REVIEW
M Asif A Siddiqui, Susan J Keam
Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. While the exact mechanism of action of ranolazine is not known, its antianginal and anti-ischaemic effects do not appear to depend upon changes in blood pressure or heart rate. An extended-release (ER) oral formulation of ranolazine has been developed to facilitate twice-daily administration whilst maintaining therapeutically effective plasma concentrations...
2006: Drugs
https://www.readbyqxmd.com/read/15816511/ranolazine-cv-therapeutics
#15
Mario Marzilli
CV Therapeutics, under license from Roche (formerly Syntex), is developing ranolazine (Ranexa), a metabolic modulator and a partial fatty acid oxidation inhibitor, for the potential treatment of angina and acute coronary syndromes. By October 2004, enrollment in the phase III MERLIN TIMI-36 study was ongoing and the company anticipated completion by the end of the first quarter of 2005.
March 2005: Current Opinion in Investigational Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"